

Special Issue

Antibody Drug Conjugates

Message from the Guest Editor

Antibody drug conjugates (ADCs) are a promising class of biotherapeutics for the treatment of diseases, such as cancer. Pairing potent drugs with antibodies through covalent attachment generates a unique therapeutic molecule, where the antibody provides cell-selectivity and extended serum half-life, while the drug provides a potent inhibitor of metabolism. “Piggybacking” potent small molecule drugs onto large antibody carriers has allowed new drugs to be used for cancer treatment (such as auristatins, tubulysins, PBDs, and duocarmycins) that present challenges as small molecule therapies alone. Recently fueled by the clinical success of Kadcyla and Adcetris. This Special Issue of *Antibodies* focuses on recent advances in ADC technology, including drug-linker design, warhead selection, conjugation approaches, antibody engineering, target selection, clinical manifestation, and other aspects related to ADCs. Dr. R. James (Jim) Christie

Guest Editor

Dr. R. James Christie

Department of Antibody Discovery and Protein Engineering,
MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA

Deadline for manuscript submissions

closed (15 December 2017)



Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



mdpi.com/si/9630

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)





Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)